YARW (Yarrow Bioscience) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

YARW Yarrow Bioscience Inc YARW
8 GF Score
Price $32.99
View Full Analysis

What is Yarrow Bioscience LT-Debt-to-Total-Asset?

Yarrow Bioscience YARW +8.34% 8 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates YARW with a GF Score™ of 8/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Yarrow Bioscience's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

Yarrow Bioscience's long-term debt to total assets ratio stayed the same from . 20 (0.00) to Dec. 2025 (0.00).

Yarrow Bioscience  (NAS:YARW) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Yarrow Bioscience LT-Debt-to-Total-Asset Related Terms

Yarrow Bioscience LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Yarrow Bioscience's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yarrow Bioscience LT-Debt-to-Total-Asset Chart

Yarrow Bioscience Annual Data
Trend Dec25
LT-Debt-to-Total-Asset
0.00

Yarrow Bioscience Semi-Annual Data
Dec25
LT-Debt-to-Total-Asset 0.00
YARW
8GF Score
Yarrow Bioscience Inc YARW
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yarrow Bioscience LT-Debt-to-Total-Asset Calculation

Yarrow Bioscience's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0/100.407
=

Yarrow Bioscience's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=0/100.407
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Yarrow Bioscience (YARW) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Yarrow Bioscience and its competitors.
Is Yarrow Bioscience's LT-Debt-to-Total-Asset too high?
Yarrow Bioscience's current LT-Debt-to-Total-Asset is 0.00. Overall, Yarrow Bioscience has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's LT-Debt-to-Total-Asset compare to ?
Yarrow Bioscience's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Yarrow Bioscience and its competitors. Yarrow Bioscience's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Yarrow Bioscience's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yarrow Bioscience Business Description

Comparable Companies
Address 251 Little Falls Drive, County of New Castle, City of Wilmington, DE, USA, 19808
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
8GF Score

Get the complete analysis for YARW

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.99
Price